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Abstract
Alport syndrome (AS) is an inherited type IV collagen nephropathies characterized by
microscopic hematuria during early childhood, the development of proteinuria and progres-
sion to end-stage renal disease. Since choosing the right therapy, even before the onset of
proteinuria, can delay the onset of end-stage renal failure and improve life expectancy, the
earliest possible differential diagnosis is desired. Practically, this means the identification of
mutation(s) in COL4A3-A4-A5 genes. We used an efficient, next generation sequencing
based workflow for simultaneous analysis of all three COL4A genes in three individuals and
fourteen families involved by AS or showing different level of Alport-related symptoms. We
successfully identified mutations in all investigated cases, including 14 unpublished muta-
tions in our Hungarian cohort. We present an easy to use unified clinical/diagnostic terminol-
ogy and workflow not only for X-linked but for autosomal AS, but also for Alport-related
diseases. In families where a diagnosis has been established by molecular genetic analy-
sis, the renal biopsy may be rendered unnecessary.
Introduction
Familiar Benign Haematuria (FBH) and Alport syndrome (AS) are familial hematuric diseases
which in case of AS regularly escalate to chronic kidney disease (CKD) stage 5 (formerly
referred as end stage renal disease). AS patients usually have sensorineural high-tone deafness
and ocular abnormalities affecting the lens and fundus [1,2].
Today, more focus has been placed on treating patients early to prevent or delay future end
stage kidney damage. Although, the pathogenesis of CKD is multifactorial, some of the sug-
gested therapeutic interventions (anti-hypertensive therapy, glycemic control, anti-proteinuric
therapy, renoprotection, and life style management such as restricted protein intake, cessation
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of cigarette smoking and chronic analgesic-abuse) are encouraging. These preventive steps the
more earlier are implemented the more efficient they are [3–5].
There has been an old and ongoing dispute to differentiate between AS and FBH based on
the wide spectra of observed clinical symptoms, microscopic analysis of renal biopsy, immuno-
logical examination and family history [6]. The first observed clinical signs are postponed by
the fact that in the intrauterine life our glomerular basal membrane does not contain
COL4A3-A4-A5, but COL4A1 and COL4A2. First symptom of AS is hematuria which appears
usually 10–15% of cases in the first year of life, while the majority of patients show symptoms
only around 5–7 years of age [7]. Because of this late manifestation and similarity between
early symptoms of AS and FBH neither clinical nor histological methods are appropriate for
early diagnosis. However, the correct genotyping can give an informed clue for the expected
progression of the disease, aid the determination of mode of inheritance useful to the family
members showing yet no symptoms, and most crucially is unavoidable for kidney donor selec-
tion [7,8].
In order to determine the mode of inheritance of AS and/or FBH a pathogenic mutation(s)
in the COL4A5 gene present on X chromosome or mutations in either the COL4A3 or COL4A4
genes on chromosome 2 should be found [9]. The most common form of AS, with approxi-
mately 4 in every 5 cases, is inherited in an X-linked fashion. X linked carrier females usually
show variable intermediate phenotype. Due to imbalances in random X inactivation the pheno-
type can vary even between family members. In case of FBH, the mode of inheritance is autoso-
mal dominant, and this disease is caused by a single heterozygous mutation either in COL4A3
or in COL4A4 genes [10]. If there are two mutations either in COL4A3 or COL4A4 genes,—a
more severe—form of AS develops. Because of this FBH can be viewed as the carrier state of
AS. There are very few reports in the literature, the vast majority of which from the pre-next
generation sequencing (NGS) era where autosomal dominant form of AS reported, and only
one mutation was found in either the COL4A3 or COL4A4 gene. Up to now it is not clear
whether this form of AS may only be the result of prior technical limitations or it is real, which
can be solved only with sequence-based analysis of larger data set and with the introduction of
a new technology [11].
Here we focus on the improvement of genetic diagnosis of type IV collagenopathies, AS and
FBH [12]. Sequential (one by one) genetic testing for mutations in COL4A3-A4-A5 genes has
become an integral part of the clinical evaluation. In our previous study on type IV collageno-
pathies we detected large number (more than a dozen) of non-synonymous variants in each
individual in these 3 genes, therefore the distinction between causative mutations and benign
variants is crucial [13]. Since all three genes are large (contains 52, 48 and 51 exons, respec-
tively) the use of conventional Sanger sequencing is time-consuming, expensive and can suffer
from some technical limitation (such as failing to detect insertion/deletion with certain sizes in
a heterozygote subject). One way to overcome these problems is to sequence all three genes
simultaneously using NGS [14].
In this paper our aim is three-fold. First, we present a new, efficient, amplicon based NGS
protocol for simultaneous analysis of the coding regions (all the exons and flanking intronic
sequences) of the COL4A3, A4 and A5 genes since a previously published NGS-based approach
failed to detect mutations in 45% of their cases [11]. Both mutations and polymorphisms in the
3 investigated COL4A genes are thought to be highly population-specific due to the lack of
selection pressure in case of the polymorphisms and low selection pressure in case of FBH.
Thus, in order to further aid the classification of COL4A3-A4-A5 genetic variations, we present
COL4A3-A4-A5 polymorphisms of 66 unrelated Hungarian non AS/FBH patients’ data
obtained by NGS. Finally, we set the task of identifying the genetic causes of 17 Hungarian
NGS-Based Differential Diagnosis of Alport/FBH
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AS/FBH independent cases, analyzing 17 AS/FBH patients using our NGS panel and Sanger
validation of 55 additional family members.
Materials and Methods
In accordance with Hungarian regulations written informed consent was obtained from each
patient in the framework of a genetic counseling session. The study protocol adhered to the
tenets of the Declaration of Helsinki and was approved by the regional ethical committee (Ethi-
cal board of University of Szeged)
Patients
Our Hungarian cohort consisted of 3 individuals (I1-I3, where family members were not avail-
able for either clinical or genetic analyses) and 14 COL IV nephropathy families (F1-F14)
where clinical data and inheritance of clinical symptoms supported Alport/FBH diagnosis
while other possible clinical causes were excluded. All volunteer family members underwent
urinalysis and renal function evaluation. Kidney biopsy was not performed on all proband. All
available clinical and pathological information is summarized in Table 1. After obtaining writ-
ten informed consent peripheral blood samples were collected from both the affected and unaf-
fected members of the families. We used anonymised DNA samples from our licensed biobank
for the 66 Hungarian non AS/FBH control samples. Criteria for FBH: mild persistent haema-
turia (25–30 RBC/HPF), mild (0.5–1.0 g/day) or no protenuria, first appereance after 10 years
of age. Criteria for Alport: persistent haematuria (>30, 50–100 RBC/HPF), persistent prote-
nuria (0.5–5.0 g/day).
Methods
The genomic DNA from peripheral blood leucocytes was isolated by a salting out procedure.
In our earlier study we made genetic test to confirm the co-segregation pattern of hematuria
with STR markers and LOD score analysis and we performed mutation screening with High
Resolution Melting (HRM) analysis and Sanger sequencing of a different set of COL4A5 fami-
lies [13]. Here we used an alternative method sequencing coding regions and the flanking splice
region of the COL4A3, COL4A4, and COL4A5 genes by new generation sequencer. Based on
the family tree, initially we choose one proband from each family (proteinuria:>0.5 g/day;
hematuria 25–30 red blood cell/high power field (RBC/HPF) for the NGS.
Our AS/FBH panel consisting of all the three COL4A3-4-5 genes was designed using the Ion
AmpliSeq™ Designer version 4.2.1 from Life Technologies. Gene enrichment was performed by
the AmpliSeq amplicon based target enrichment system. Sample enrichment was performed by
the Ion AmpliSeq(TM) Library Kit, Life Technologies. The samples were barcoded and
sequenced on IonTorrent 316 chip. We aimed for at least 25 times coverage (more than 90% of
the target were covered at least 100 times and more than 95% of the target were covered at least
50 times). Bioinformatical analysis was performed by CLC Bio, Torrent Suite 4.2 and Illumina
VariantStudio softwares.
To confirm and evaluate the putative disease causing genetic variations we designed primers
by Primer3Plus software and executed PCR amplification for all members of our cohort [15].
PCR products were purified using High Pure PCR Product Purification Kit, (Roche) and
sequenced on Applied Biosystems HITACHI 3500 Genetic Analyzer. For visualization of the
Sanger sequencing we used FinchTV (Geospiza Inc.).
We compared the results with the following public databases: HGMD [16], LOVD [17],
1000Genomes.org [18], Alport database (ARUP) [19]. All the previously unpublished mutation
were submitted in LOVD database (http://grenada.lumc.nl/).
NGS-Based Differential Diagnosis of Alport/FBH
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Table 1. Clinical and pathological details of the investigated Hungarian AS/FBH families.
Family Individuals Age Hematuria Proteinuria Renal function Biopsy, histology hearing
F1 I/2 36 yrs microhematuria none normal none normal
II/2 3 yrs persistent
hematuria
none normal At age 3 could not discriminate
between AS or TBMN
normal
F2 I/1 58 yrs none none normal not performed normal
II/2 31 yrs microhematuria yes normal At age of 31 TBMN was suggested normal
F3 I/2 53 yrs hematuria none normal At age 7: suggested TBMN ND
II/1 32 yrs hematuria yes on dialysis At age 17: suggested TBMN ND
II/2 30 yrs hematuria 0.5 g/day eGFR 90 (CKD Stage
1), had transplantation
and now on dialysis
not performed ND
F4 I/1 38 yrs microhematuria no normal level of se-
creatinine
not performed mild right-side
and moderate
left-side
hipacusis
II/1 15 yrs ND ND on dialysis since age of
15
not performed bilateral mild
hipacusis
II/2 13 yrs hematuria 5 g/day at
age of 13
At age of 18 diffusely thin GBM,
basket weaving in several loops, α3
chain was entirely absent, α5 chain
exhibited very focal expression
ND
II/3 16 yrs microhematuria ND normal ND normal at age of
29
F5 I/2 86 yrs hematuria ND ND ND ND
II/3 61 yrs hematuria ND ND ND ND
II/4 hematuria ND ND ND ND
III/2 30 yrs ND ND kidney transplantation at
age of 31
ND ND
IV/1 17 yrs hematuria yes no kidney
transplantation at age of
25
ND normal at age of
25
IV/2 and IV/3
twins
16 yrs ND ND both had kidney
transplantation at age of
16
ND ND
F6 II/1 died at
age 13
13 yrs ND ND ND ND ND
II/5 21 yrs hematuria yes ND At age 11; not conclusive ND
F7 I/1 80 yrs none none se-creatinine normal not performed ND
I/2 49 yrs 10–12
dysmorphic RBC/
hpf
yes se-creatinine normal At age of 49 diffusely thin GBM,
glomerular scars
moderate
bilateral hearing
loss
II/2 60 yrs 10–15
dysmorphic RBC/
hpf
yes se-creatinine normal not performed ND
II/4 62 yrs 10–15
dysmorphic RBC/
hpf
none ND not performed ND
III/1 46 yrs 8–10 dysmorphic
RBC/hpf
none se-creatinine normal At age of 46 diffusely thin GBM bilateral hearing
loss
III/3 42 yrs hematuria yes ND not performed ND
III/4 40 yrs hematuria ND ND ND ND
III/6 47 yrs 30–35
dysmorphic RBC/
hpf
1.5 g/day se-creatinine normal At age of 47 diffusely thin GBM,
doubled in some loops
bilateral hearing
loss
(Continued)
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Table 1. (Continued)
III/8 44 yrs hematuria ND ND not performed ND
III/9 42 yrs 25–30
dysmorphic RBC/
hpf
0.8 g/day se-creatinine normal At age of 42 diffusely thin GBM moderate
bilateral hearing
loss
IV/1 17 yrs 8–10 dysmorphic
RBC/hpf
3 g/day se-creatinine normal At age of 17 diffusely thin GBM,
with splitting in some loops
moderate
bilateral hearing
loss
IV/2 24 yrs 8–10 dysmorphic
RBC/hpf
3 g/day se-creatinine normal At age of 24 diffusely thin GBM,
with splitting in some loops
bilateral hearing
loss
IV/3 36 yrs hematuria ND ND not performed normal
IV/7 15 yrs 50–60
dysmorphic RBC/
hpf
0.8 g/day se-creatinine normal At age of 15 diffusely thin GBM moderate
unilateral
hearing loss
V/1 4 yrs persistent
hematuria
ND ND not performed normal at age of
4
F8 I/1 38 yrs hematuria ND ND not performed normal
II/1 5 yrs hematuria ND ND not performed normal
II/2 12 yrs 100 RBC/hpf ND ND not performed normal
F9 I/1 71 yrs hematuria ND ND not performed ND
II/2 45 yrs hematuria ND ND At age of 32 could not conﬁrm
either AS or TBMN
ND
III/1 16 yrs hematuria ND ND At age of 3 TBMN was suggested ND
F10 II/1 65 yrs hematuria ND ND not performed ND
II/2 67 yrs hematuria ND ND not performed ND
III/2 44 yrs hematuria ND ND not performed ND
IV/1 12 yrs hematuria ND ND not performed mild hipacusis
F11 I/1 50 yrs 30 RBC/hpf ND ND not performed ND
II/1 24 yrs 30 RBC/hpf yes ND At age of 24 secondary FSGS,
likely TBMN but could not exclude
AS
normal
II/2 15 yrs 30 RBC/hpf yes decreasing eGFR ND ND
F12 II/1 69 yrs hematuria none ND not performed normal
II/3 71 yrs hematuria none ND not performed normal
II/5 68 yrs hematuria none ND not performed normal
III/3 37 yrs hematuria none ND At age of 42 TBMN was suggested normal
III/6 42 yrs hematuria none ND not performed normal
III/7 35 yrs hematuria none ND not performed normal
III/8 39 yrs hematuria none ND not performed normal
F13 I/1 38 yrs hematuria no ND ND normal
II/2 6 yrs hematuria no ND ND normal
F14 I/2 35 yrs microhematuria no ND not performed ND
II/1 2 yrs microhematuria at
age of 3
no ND not performed ND
Individuals Age Hematuria Proteinuria Renal function Biopsy, histology hearing
I1 35 yrs hematuria yes ND not performed ND
I2 38 yrs microhematuria 0.8 g/day ND not performed ND
I3 1 yr hematuria none ND not performed ND
RBC—red blood cell; eGFR—estimated glomerular ﬁlter rate; CKD—chronic kidney disease; ND—no data; hpf–(microscopic) high power ﬁeld; FSGS—
focal segmental glomerulosclerosis, GBM—Glomerular basement membrane, AS—Alport syndrome, FBH—Familiar Benign Hematuria. There was no
data on eye sight problems in the patients.
doi:10.1371/journal.pone.0149241.t001
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In this study a genetic variant pathogenicity was concluded if the observed mutation:
1. was published previously or found in mutation databases
2. was not found among controls
3. it is not a common allele found in either dbSNP or in Exome Variant Server or in the scien-
tific literature
4. its exclusive presence among affected family members was genetically proven.
We have not judged pathogenicity of any mutation by prediction programs.
Results
AS/FBHMultiplex AmpliSeq panel
Our AS/FBH AmpliSeq panel is designed for standard (not formalin-fixed paraffin embedded
(FFPE)) DNA, with amplicon size range of 125–225 bp. The designed 197 amplicons were
organized into two (99 and 98) pools. Our targets (all three genes coding exonic regions with
15 bp padding) were as follows: 5,013 bp COL4A3 (covering 96.361% of the planned region),
5,073 bp COL4A4 (97.02% covering) and 5,383 bp COL4A5 (98.86% covering). The overall tar-
get size was 29.4 kb with an average coverage of 97.63%.
Analysis of Hungarian non AS/FBH cohort
By analyzing the 66 Hungarian non AS/FBH controls we wished to identify population-specific
polymorphisms in order to help distinguish polymorphisms from causative mutations in our
AS/FBH cohort. We have found 21 unique non-synonymous exonic and intronic genetic vari-
ances within the investigated COL4A3, COL4A4 and COL4A5 genes. We identified 11 genetic
variants in COL4A3, 9 variants in COL4A4 and only one in COL4A5 gene. All of them were
already published elsewhere (Table 2).
Variation classification workflow
The available medical records and the predictive clinical and pathological results are often
incomplete or not conclusive enough to distinguish between FBH and the different types of
Alport (autosomal or X-linked), especially in not-so-large families (see Table 1 and Fig 1)
Therefore, we decided to do sequencing-based genetic analysis on the Hungarian AS/FBH
cohort using our AmpliSeq panel. Selection criteria for individuals for the initial NGS analysis
were as detailed in Methods. Then, as results of NGS analysis all the identified unique 37
genetic alterations were compared to data of publicly available databases such as LOVD,
dbSNP, HGMD and Alport database (University of Utah). As a result we identified the 21 pub-
lished, previously mentioned polymorphisms (Table 2) and 4 published mutations (2 in
COL4A4 and 2 in COL4A5 genes). All the four published mutations were validated in the
appropriate AS/FBH cases, where we confirmed that only affected individuals carried them.
The 14 remaining alterations were investigated among AS/FBH family members. We have clas-
sified all of these alterations as new mutations (5 in COL4A3 gene; 3 in COL4A4 and 6 in
COL4A5 genes) as their exclusive presence was confirmed in the affected family members by
Sanger sequencing (see individual family trees in Supplements). Six out of the thirteen SNP
mutations were amino acid change (missense mutations), while the remaining seven SNP
mutations were found in the splice recognition sites (splice variants). We also identified a
COL4A4mutation affecting part of exon 20 and 2 bases in the splice donor site that is a 52 bp
deletion shortening the exon and altering splicing (Table 3).
NGS-Based Differential Diagnosis of Alport/FBH
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To demonstrate the ease and usefulness of our methodology, we categorized all of the 14
families as follows: F1, F5-7, F9-11 and F14 have X-linked AS; F3 and F4 have autosomal semi-
dominant AS; F2, F8, F12 and F13 have FBH (see Fig 1A–1C). We had no information about
additional family members in the individual (I1-I3) cases, but using our genetic diagnostic
approach we could categorize them as X-linked AS (I1 and I2) and FBH (I3).
Discussion
AS and FBH are inherited renal diseases, with an incidence rate of 1:50,000 in case of AS and
around 1:200 in case of FBH [33,35]. Type IV collagen is an important structural protein in
basement membranes, has a triple helical structure, which consists of a Col4A3, a Col4A4 and
a Col4A5 protein [36]. Since COL4A3 and COL4A4 genes are coded in an autosomal
Table 2. List of the identified polymorphisms in the investigated non AS/FBH cohort.
Gene Variant MAF Consequence Published
in
Family (F) or Individual (I)
COL4A3 c.127G>C 0.153 p.Gly43Arg [20] F1 (M), F5 (M), F6 (M), F10 (M), F13 (M)
c.1721C>T 0.121 p.Pro574Leu [21] F1 (M), F5 (M), F2 (F), F4 (F), F8 (F), F10 (M), F11 (F), F12 (F), F13 (M), F14 (F), I1
(M), I2 (M), I4, F1 (M), F5 (M)
c.3325C>T 0.024 p.Pro1109Ser [22] F4 (F)
c.547-9A>C 0.024 IV rs55667591 F3 (F), F4(F)
c.3807C>A 0.040 p.Asp1269Glu [21] F2 (F), F6 (M)
c.976G>T 0.226 p.Asp326Tyr [23] F3 (F), F6 (M), I3 (M), F7 (M), F13 (M), F11 (F), F8 (F)
c. 2384-5T>C 0.113 IV [24] F10 (M), F7 (M)
c.485A>G 0.798 p.Glu162Gly [25] F3 (F), I1 (F), F6 (M), F7 (M), F11 (F), F9 (F), F1 (M), F2 (F), F10 (M), F4 (F), I2 (M),
F5 (M), F12 (F), F12 (F), I3 (M), F8 (F), F13 (M), F13 (F)
c. 144
+12C>A
0.339 IV [25] F8 (F) F3 (F), F10 (M), I1 (F), I2 (M), F6 (M), I3 (M), F13 (M), F11 (F), F9 (F)
c.422T>C 0.798 p.Leu141Pro [22] F1 (M), F2 (F), F10 (M), F4 (F), I2 (M), F5 (M), F12 (F), F12 (F), I3 (M), F8 (F), F13
(M), F13 (F), F3 (F), I1 (F), F6 (M), F7 (M), F11 (F), F9 (F)
c. 1352A>G 0.105 p.His451Arg [21] I2 (M), F9 (F)
COL4A4 c.2717-5A>T 0.040 IV [26] F11(F)
c.2501A>G 0.008 p.Lys834Arg [27] F11 (F)
c. 4207T>C 0.355 p.Ser1403Pro [28] F2 (F), F3 (F), I1 (F), I2 (M), F5 (M), F12 (F), F6 (M)F10 (M), F4 (F), F12 (F), F7 (M)
c.3817+9G>C 0.363 IV [29] F1 (M), F10 (M), F4 (F), I3 (M), F7 (M), F13 (F)
c.3979G>A 0.363 p.Val1327Met [20] F1 (M), F10 (M), F4 (F), F12 (F), I3 (M), F7 (M), F13 (F)
c 1444C>T 0.435 p.Pro482Ser [20] F2 (F), F10 (M), I1 (F), I2 (M), F12 (F), F7 (M) F1 (M), F3 (F), F5 (M), F12 (F), F6
(M), F13 (F), F11 (F)
c.3011C>T 0.444 p.Pro1004Leu [20] F2 (F), F3 (F), F10 (M), I1 (F), I2 (M), F5 (M), F12 (F), F6 (M), F7 (M), F1 (M), F4 (F),
F12 (F), I3 (M), F13 (M), F13 (F)
c.2996G>A* 0.008 p.Gly999Glu [30] F4 (F)
c.4394G>A** p.Gly1465Asp [11] F3(F)
COL4A5 c.2768-
11A>G
0.065 IV [31] F3 (F), I1 (F), F10 (M), I2 (M), I3 (M)
minor allele frequency; IV: intronic variant; F: female; M: male)
* variant effect remained uncertain since we have found it in a control person (age 13 with two negative urinal samples, but we could not rule out later
manifestation of FBH).
** this is a rare genetic variant with uncertain consequences. It was published both as polymorphism and as pathogenic mutation. In Family 3 this variant
is co-segregating with a known pathogenic mutation (c.2320G>C), so we can not elaborate on the consequence of this variant when it is occurring
separately.
doi:10.1371/journal.pone.0149241.t002
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chromosome, a single mutation in any of these two genes only leads to FBH in both sexes, as
half of the triple helix has normal structure. However, a single mutation in X chromosome
coded Col4A5 protein will lead to AS in males (disrupting all forming triple helix) and varying,
intermediate phenotype in females. Genetically FBH is a special carrier form of AS since it also
causes phenotype (not like in classical recessive metabolic diseases such as PKU) and tradition-
ally treated as independent disease. Successful identification of genetic mutation in any of these
3 COL4A genes—even before the clinical signs can be observed—could provide an early differ-
ential diagnosis for FBH/Alport patients.
We established a new, amplicon based NGS method which has three advantages: 1, it is reli-
able, cheaper (less than 500 euro per sample) and faster than the traditionally used Sanger cap-
illary sequencing, 2, can provide DNA sequence information from all three COL4A genes
simultaneously and 3, has the potential to detect single nucleotide polymorphisms (SNPs) and
various sizes of insertions/deletions as well. Using our NGS panel and the approach outlined in
this paper we successfully identified causative mutations in all investigated AS/FBH instances.
In our study 37 genetic variations were identified from which there are 14 unpublished and
3 published mutations, thus causative mutations were successfully identified in all investigated
cases. Out of our 17 cases 10 (as was expected) were X-linked AS (caused by 8 different
COL4A5mutations), we had 5 FBH cases (3 with three different COL4A3 and 2 with two
Fig 1. Pedigree of investigated AS/FBH Hungarian families. A, Families with X-linked AS. B, Families with autosomal AS. C, Families with FBH. Open
squares indicate males and open circles indicate females. An oblique bar indicates a deceased individual. White symbols indicate individuals without clinical
sings of the AS/FBH disease. Filled black symbols denote individuals with hematuria and/or proteinuria, hypoacusis or renal failure. The segment shaded
circles and squares indicate carriers for a Chromosome 2 (COL4A3 or COL4A4) mutation. A circle that has a dot inside indicates a COL4A5mutation carrier.
The plus signs indicate the index patients whose DNA was analyzed by NGS. The identified mutation(s) for each family is shown.
doi:10.1371/journal.pone.0149241.g001
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different COL4A4mutations). In case of Family 4 we have identified two COL4A3mutations,
while in Family 3 we have identified two COL4A4mutations causing autosomal AS in both
cases. In our cohort we not only detected non-synonymous (amino acid change) SNPs and
splice mutations, nine and seven respectively, there was also a 52 bp deletion revealed. Eight
amino acid changes caused Glycine substitution in collagenous domains, what is a well-known
pathogenic alteration in Col4A proteins. Interestingly, a missense mutation (c.82G>T; p.
Ala28Ser mutation in family 11, which also alters a conserved base of the splice acceptor site)
was detected in a non-collagenous domain of Col4a5, which segregation was coherent with the
observed clinical symptoms in the family. In two other cases the splice regions within exons, in
two cases splice donor sites, while in 3 cases splice acceptor sites were affected. There was a
COL4A5 splice site mutation variant which is outside the usual +/- 1–2 splice donor/acceptor
site (c.1033-6G>A in Family 7), that although fulfilled all of our mutation classification criteria
(detailed in Material and Methods) without additional functional test we only presumed that it
is pathogenic.
Up to now there are less than 1000 classified causative variants in public databases (HGMD,
dbSNP, ClinVar) regarding the three COL4A genes causing AS/FBH which are around 4% of
the whole exonic target region. The vast majority of the published mutations coming from X-
linked COL4A5 data, even if either of the two autosomal COL4A genes is longer and their
mutations can cause not only the more frequent FBH but also AS as well. One of the possible
explanations could be that lots of FBH cases (caused by a single mutation either of COL4A3 or
COL4A4) remain undiagnosed. With the introduction of simultaneous sequencing of all three
COL4A genes by NGS, we should expect more sequence data from COL4A3 and A4 in the near
future. Both mutations and polymorphisms in the 3 investigated COL4A genes are thought to
be highly population-specific (due to non-existing selection pressure in case of the polymor-
phisms and only low selection pressure in case of FBH). But, to our surprise, none of the 21
identified genetic variations in our control group proved to be unpublished and Hungarian
Table 3. List of the identified mutations in our Hungarian AS/FBH cohort.
Gene Variant Consequence Family/Individual Published in
COL4A3 c.687G>A splice region F4(F) this paper
c.3490G>T p.Gly1164Cys F4(F) this paper
c.765+2T>C splice donor F12(F) this paper
c.3410G>A p.Gly1137Asp F13(M) this paper
c.765G>T splice region F2(F) this paper
COL4A4 c.2320G>C p.Gly774Arg F3(F) [32]
c.2986G>A p.Gly996Arg I3(F) this paper
c.1100-2A>C splice acceptor F8(F) this paper
c.1320_1369+2del deletion, splice donor F3 (F) this paper
COL4A5 c.1780-1G>T splice acceptor F9(F) this paper
c.1871G>A p.Gly624Asp F10(M), F14(F), I2(M) [33]
c.1033-6A>G presumed splice variant F7(M) this paper
c.2395+1G>A splice donor F5(M) this paper
c.1094G>A p.Gly365Glu F1(M) [34]
c.2741G>A p.Gly914Asp F6(M) this paper
c.82G>T p.Ala28Ser/ splice acceptor F11(F) this paper
c.1010G>T p.Gly337Val I1(M) this paper
(F: female; M: male)
doi:10.1371/journal.pone.0149241.t003
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population specific. In scientific literature an autosomal dominant (AD) form of AS is also
mentioned. Most of the autosomal dominant AS data comes from an era where the technical
limit (error rates) of sequencing was comparable to the claimed frequency (around 1%) of this
form of AS. However, a recent paper using NGS claims that there was an astonishing portion
of autosomal dominant AS (31%) of their solved cases [10]. In the light of these data we should
expect to find around 5 AD AS among our 17 cases, but we have not found any.
In our opinion there is a widespread confusion in the clinical and pathological terminologies
used to describe FBH, Thin Basement Membrane Nephropathy (TBMN) and AS. FBH is used
by nephrologist as a descriptive term for cases when only haematuria (usually non progressive,
without proteinuria or impaired hearing or vision) could be detected throughout the family,
which is only a subset (although the largest) of all the TBMN cases. TBMN on the other hand
is a term used by pathologists describing the thin basement membrane phenomenome of the
kidney, which in some cases result slowly progressive haematuria with proteinuria and as an
age-related process can reach ESRD in elderly patients. In their paper Fallerini C. et al pre-
sented 7 AD AS families in detail with a single identified autosomal COL4A3 or A4mutation
[11]. Their conclusion could be biased by the fact that 45% of their AS/FBH cases went without
mutation identification. It is also worth to note that in all of their published AD AS cases ESRD
presented only in older age (between 52–74 with an average of 63 years), without a single case
with eye problem and with only 4 elderly cases with hearing loss. According to WHO data
(updated in 2015 march) approximately one-third of people over 65 years of age are affected
by disabling hearing loss which is fully agrees with their reported rate.
Further on there is no known explanation for the biological foundation of AD AS. In cases
where collagen triple helix formed by one (as in case of Type VII collagen, 3 identical chains
coded by COL7A1 gene) or two different collagen chains (as in case of Type I collagen, consist-
ing of two chains coded by COL1A1 and one coded by COL1A2) the dominant negative effect
of a single autosomal mutation is known [37,38]. In these cases, due to the formation of homo-
dimers/homotrimers, a single mutation in an autosomal gene could lead to stronger phenotype
than a null allele. The mutated protein will bind to the normal protein and result only around
25% of functional dimer (and even less in case of trimers) while autosomal null alleles lead to
~50% functional protein in heterozygotes. This is not the case in the forming Col4a3-4-5 triple
helix, where all three chains are different and coded by different genes, so it does not comply
with the current biological model of negative dominant effect. FBH biologically is the result of
reduced amount of proper Col4a3-4-5 triplex, while AS is the result of the lack of the functional
protein.
Based on our own observation on the genetic analyses presented here; confusing interpreta-
tion on age related clinical symptoms and the lacking of biological foundation we think that
AD AS as genetic term doesn’t exist and shouldn’t be used. We think that the alleged autosomal
Alport cases genetically are either a single severe autosomal mutation leading to phenotype in
between FBH/AS only in higher age (so it is a slowly evolving TBMN) or it could also be the
result of unsuccessful genotyping of autosomal AS due to technical (for example the use of inef-
fective insertion/deletion detection algorithm) or differences in their genetic variation classifi-
cation approach that heavily relies on prediction softwares.
As far as we see Alport syndrome and its related diseases and their observed clinical/
pathological heterogeneity (heamaturia, ESRD, hypoacusis, TBMN) is such a biological prob-
lem, which has quantitative inheritance elements. In individuals without mutations in the three
investigated COL4A genes has the full amount of fully functional triple-helix. In the individuals
(independently from gender) with a mutation in either COL4A3 or COL4A4 gene there is
about half of the theoretical maximum amount of functional triple-helix. If there is a COL4A5
mutation in a male, than there isn’t any fully functional triple-helix formed. In females, since
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random inactivation of X chromosome occurs, approximately 50% of fully functional triple-
helix will form, but this could be altered (positively or negatively) by the imbalances of X inacti-
vation. This also could explain the variable phenotype even in a family. The situation in the
case of extracellular basal membrane is even more complex, since the observed clinical pheno-
type does not depend on a single cell genotype rather from the genotype ratio within Type IV
collagen producing cell population. The other sources of the heterogenity naturally are the
mutations causing different level of malfunction in the forming triple-helix. This phenotypic
variablity leads to introduce the term semi-dominant inhertance, which has an intermediate
phenotype different from both dominant (since the phenotype of a heterozygote is not the
same as a homozygote mutant) or recessive (since the phenotype of a heterozygote is not the
same as a homozygote normal). As a result of this we can view Alport and its related diseases as
a spectrum disorder, where the biological base of the different phenotypes is the amount of
fully functional (or impared/null) Type IV collagen formed. The two extremities of this spec-
trum are FBH with only mild, non-progressing haematuria, while the other end is Alport syn-
drome with serious kidney, eye and hearing phenotype.
Because the prognosis of FBH and AS is entirely different while the early symptoms could
be similar, both the genetic classification and the above mentioned distinction in our view is
extremely important. By providing correct genetic data and by establishing the correct inheri-
tance pattern within family, it could help both clinicians and genetic counselors 1) to commu-
nicate and make an early, informed decision about the possible speed and direction of the
progression in the family, 2) to establish the circle of the family members who need regular
checking, 3) to select a possible kidney donor within the family and 4) support positive family
planning. The genetic test could lead to the earliest diagnosis even before the manifestation of
clinical symptoms that would be a big benefit for patients, for their families and for the health
systems as well. For patients with some of the earlier clinical symptoms or even before, genetic
diagnosis could mean preventive treatment such as using ACE inhibitors which could delay
the onset of end-stage renal failure and improve life expectancy, even when begun before the
onset of proteinuria [5,6,26]. For family members the biggest benefit could be the possibility
for positive family planning, and the awareness of possible kidney problems. And for the health
system the cheap genetic diagnostic procedure eliminates the need for long and uncertain clini-
cal staying, and lots of unnecessary, less conclusive and much more expensive tests and exami-
nations. The best tool for this job is the DNA-based molecular genetic analysis of the proband
and his/her relatives. Using peripheral blood as DNA source for genetic analysis causes much
less trauma for patient (especially children) compared to the kidney biopsy, which carries cer-
tain level risk of severe complications [27]. The result of the DNA sequencing is independent
of the age of the proband, from the stage of the disease and in most cases provides quick and
accurate confirmation of the diagnosis. It can be also performed on a single person indepen-
dently when the family history is not available. Furthermore, in cases where no detailed clinical
and pathological data is available genetic analyses could be the first choice.
We believe that our classification approach and the presented genetic data could contribute
to better, faster and cheaper diagnosis of AS/FBH patients and their relatives. In order to fur-
ther facilitate the mutation detection rate in AS/FBH our AmpliSeq panel was offered as pub-
licly available panel (Ion Community Panel) in the AmpliSeq Designer site (www.ampliseq.
com) and see also S1 File.
Supporting Information
S1 File. Our custom AmpliSeq Alport-panel design files.
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NGS-Based Differential Diagnosis of Alport/FBH
PLOSONE | DOI:10.1371/journal.pone.0149241 March 2, 2016 11 / 14
Acknowledgments
We firstly thank AS/FBH syndrome families for their participation and medical doctors for
consultation. We also thank Mrs E Borzási, Mrs I Csipő, Mrs MMustoha and Mrs T Vida-
Szűcs for their expert assistance with the laboratory work. This work was supported by Hun-
garian Society of Nephrology providing a grant for young researchers (GK).
Author Contributions
Conceived and designed the experiments: EE ZM. Performed the experiments: BI TK GK ZM.
Analyzed the data: ZM GK TK. Contributed reagents/materials/analysis tools: ZO CR IH ST
MS CB. Wrote the paper: TK GK BI ZM.
References
1. Alport AC. HEREDITARY FAMILIAL CONGENITAL HAEMORRHAGIC NEPHRITIS. Br Med J. 1927;
1:504–6. PMID: 20773074
2. Reyersbach GC, Butler AM. Congenital Hereditary Hematuria. N Engl J Med [Internet]. Massachusetts
Medical Society; 1954 Sep 2; 251(10):377–80. Available from: 10.1056/NEJM195409022511003
3. Mogensen CE. Preventing End-Stage Renal Disease. Diabet Med. 1998; 15(Suppl.4):S51–6. PMID:
9868993
4. Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F. Expert guidelines for the management of
Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol [Internet]. 2013; 24(3):
364–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23349312
5. Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tönshoff B, et al. Early angiotensin-converting enzyme
inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 2012; 81(5):
494–501. doi: 10.1038/ki.2011.407 PMID: 22166847
6. Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, et al. Clinical practice recommen-
dations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collabora-
tive. Pediatr Nephrol. 2012;5–11. doi: 10.1007/s00467-012-2138-4 PMID: 22461141
7. Kashtan CE. Alport syndromes: phenotypic heterogeneity of progressive hereditary nephritis. Pediatr
Nephrol. 2000; 14(6):502–12. PMID: 10872195
8. Soininen R, Huotari M, Hostikka SL, Prockop DJ, Tryggvason K. The structural genes for alpha 1 and
alpha 2 chains of human type IV collagen are divergently encoded on opposite DNA strands and have
an overlapping promoter region. J Biol Chem [Internet]. 1988; 263(33):17217–20. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/3182844
9. Mencarelli MA, Heidet L, Storey H, van Geel M, Knebelmann B, Fallerini C, et al. Evidence of digenic
inheritance in Alport syndrome. J Med Genet. 2015; 52(3):163–74. doi: 10.1136/jmedgenet-2014-
102822 PMID: 25575550
10. Buzza M, Wilson D, Savige J. Segregation of hematuria in thin basement membrane disease with hap-
lotypes at the loci for Alport syndrome. Kidney Int [Internet]. 2001; 59(5):1670–6. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/11318937
11. Fallerini C, Dosa L, Tita R, Del Prete D, Feriozzi S, Gai G, et al. Unbiased next generation sequencing
analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases.
Clin Genet. 2013;252–7. doi: 10.1111/cge.12258 PMID: 24033287
12. Torra R, Tazón-Vega B, Ars E, Ballarín J. Collagen type IV (alpha3-alpha4) nephropathy: from isolated
haematuria to renal failure. Nephrol Dial Transplant. 2004; 19(10):2429–32. PMID: 15280517
13. Endreffy E, Ondrik Z, Iványi B, Maróti Z, Bereczki C, Haszon I, et al. Collagen type IV nephropathy:
Genetic heterogeneity examinations in affected Hungarian families. Mol Cell Probes. 2011; 25(1):28–34.
doi: 10.1016/j.mcp.2010.10.001 PMID: 20951199
14. Chatterjee R, Hoffman M, Cliften P, Seshan S, Liapis H, Jain S. Targeted Exome Sequencing Inte-
grated with Clinicopathological Information Reveals Novel and Rare Mutations in Atypical, Suspected
and Unknown Cases of Alport Syndrome or Proteinuria. PLoS One. 2013; 8(10).
15. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JAM. Primer3Plus, an enhanced
web interface to Primer3. Nucleic Acids Res. 2007; 35(SUPPL.2).
16. Stenson PD, Mort M, Ball EV., Shaw K, Phillips AD, Cooper DN. The Human Gene Mutation Database:
Building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing
and personalized genomic medicine. HumGenet. 2014; 133(1):1–9. PMID: 24077912
NGS-Based Differential Diagnosis of Alport/FBH
PLOSONE | DOI:10.1371/journal.pone.0149241 March 2, 2016 12 / 14
17. Fokkema IFaC, Taschner PEM, Schaafsma GCP, Celli J, Laros JFJ, den Dunnen JT. LOVD v.2.0: The
next generation in gene variant databases. HumMutat. 2011; 32(5):557–63. doi: 10.1002/humu.21438
PMID: 21520333
18. Consortium T, Project. An integrated map of genetic variation from 1,092 human genomes. Nature.
2012; 135(V):0–9.
19. Crockett DK, Pont-Kingdon G, Gedge F, Sumner K, Seamons R, Lyon E. The Alport Syndrome
COL4A5 variant database. HumMutat. 2010; 31(8):1652–7.
20. Longo I, Porcedda P, Mari F, Giachino D, Meloni I, Deplano C, et al. COL4A3/COL4A4 mutations: From
familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int. 2002; 61(6):
1947–56. PMID: 12028435
21. Heidet L, Arrondel C, Forestier L, Cohen-Solal L, Mollet G, Gutierrez B, et al. Structure of the human
type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol. 2001;
12(1):97–106. PMID: 11134255
22. Wang YY, Rana K, Tonna S, Lin T, Sin L, Savige J. COL4A3mutations and their clinical consequences
in thin basement membrane nephropathy (TBMN). Kidney Int. 2004; 65(3):786–90. PMID: 14871398
23. Hoefele J, Lange-Sperandio B, Ruessmann D, Glöckner-Pagel J, Alberer M, Benz MR, et al. Novel het-
erozygous COL4A3mutation in a family with late-onset ESRD. Pediatr Nephrol. 2010; 25(8):1539–42.
doi: 10.1007/s00467-010-1467-4 PMID: 20177710
24. Papazachariou L, Demosthenous P, Pieri M, Papagregoriou G, Savva I, Stavrou C, et al. Frequency of
COL4A3/COL4A4 Mutations amongst Families Segregating Glomerular Microscopic Hematuria and
Evidence for Activation of the Unfolded Protein Response. Focal and Segmental Glomerulosclerosis Is
a Frequent Development during Ageing. PLoS One [Internet]. 2014; 9(12):e115015. Available from:
http://dx.plos.org/10.1371/journal.pone.0115015
25. Badenas C, Praga M, Tazón B, Heidet L, Arrondel C, Armengol A, et al. Mutations in theCOL4A4 and
COL4A3 genes cause familial benign hematuria. J Am Soc Nephrol. 2002; 13(5):1248–54. PMID:
11961012
26. FrascàGM, Onetti-Muda A, Mari F, Longo I, Scala E, Pescucci C, et al. Thin glomerular basement
membrane disease: Clinical significance of a morphological diagnosis—A collaborative study of the
Italian Renal Immunopathology Group. Nephrol Dial Transplant. 2005; 20(3):545–51. PMID: 15618242
27. Voskarides K, Damianou L, Neocleous V, Zouvani I, Christodoulidou S, Hadjiconstantinou V, et al.
COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin
basement membrane nephropathy. J Am Soc Nephrol. 2007; 18(11):3004–16. PMID: 17942953
28. Ciccarese M, Casu D, Ki Wong F, Faedda R, Arvidsson S, Tonolo G, et al. Identification of a new muta-
tion in the alpha4(IV) collagen gene in a family with autosomal dominant Alport syndrome and hyperch-
olesterolaemia. Nephrol Dial Transplant. 2001; 16(10):2008–12. PMID: 11572889
29. Baek JI, Choi SJ, Park SH, Choi JY, Kim CD, Kim YL K U. Identification of novel variants in the
COL4A4 gene in Korean patients with thin basement membrane nephropathy. Indian J Med Res. 2009;
129(5):525–33. PMID: 19675380
30. Buzza M, Dagher H, Wang YY, Wilson D, Babon JJ, Cotton RG, et al. Mutations in the COL4A4 gene in
thin basement membrane disease. Kidney Int. 2003; 63(2):447–53. PMID: 12631110
31. Ma J, Pan X, Wang Z, Wang Y, Feng X, Ren H, et al. Twenty-one novel mutations identified in the
COL4A5 gene in Chinese patients with X-linked Alport’s syndrome confirmed by skin biopsy. Nephrol
Dial Transplant [Internet]. 2011; 26(12):4003–10. Available from: http://ndt.oxfordjournals.org/cgi/doi/
10.1093/ndt/gfr184
32. Slajpah M, Gorinsek B, Berginc G, Vizjak A, Ferluga D, Hvala A, et al. Sixteen novel mutations identi-
fied in COL4A3, COL4A4, and COL4A5 genes in Slovenian families with Alport syndrome and benign
familial hematuria. Kidney Int. 2007; 71(12):1287–95. PMID: 17396119
33. Martin P, Heiskari N, Zhou J, Leinonen A, Tumelius T, Hertz JM, Barker D, Gregory M, Atkin C, Styr-
karsdottir U, Neumann H, Springate J, Shows T, Pettersson E T K. Mutation Detection in Suspected
Alport Sequencing Rate in the COL4A5 Collagen Syndrome Using PCR and Direct DNA sequencing. J
Am Soc Nephrol. 1998;2291–301.
34. Knebelmann B, Breillat C, Forestier L, Arrondel C, Jacassier D, Giatras I, et al. Spectrum of mutations
in the COL4A5 collagen gene in X-linked Alport syndrome. Am J HumGenet. 1996; 59(6):1221–32.
PMID: 8940267
35. Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure.
Kidney Int. 2000; 58(3):925–43. PMID: 10972657
36. Sundaramoorthy M, Meiyappan M, Todd P, Hudson BG. Crystal structure of NC1 domains: Structural
basis for type IV collagen assembly in basement membranes. J Biol Chem. 2002; 277(34):31142–53.
PMID: 11970952
NGS-Based Differential Diagnosis of Alport/FBH
PLOSONE | DOI:10.1371/journal.pone.0149241 March 2, 2016 13 / 14
37. Fritsch A, Spassov S, Elfert S, Schlosser A, Gache Y, Meneguzzi G, et al. Dominant-negative effects of
COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII. J Biol Chem.
2009; 284(44):30248–56. doi: 10.1074/jbc.M109.045294 PMID: 19726672
38. Gajko-Galicka A. Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans.
Acta Biochimica Polonica. 2002. p. 433–41. PMID: 12362985
NGS-Based Differential Diagnosis of Alport/FBH
PLOSONE | DOI:10.1371/journal.pone.0149241 March 2, 2016 14 / 14
